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Background. Sulfatide is known to chaperone insulin crystallization within the pancreatic beta cell, but it is not known if this results
from sulfatide being integrated inside the crystal structure or by binding the surface of the crystal. With this study, we aimed to
characterize the molecular mechanisms underlying the integral role for sulfatide in stabilizing insulin crystals prior to exocytosis.
Methods. We cocrystallized human insulin in the presence of sulfatide and solved the structure by molecular replacement. Results.
The crystal structure of insulin crystallized in the presence of sulfatide does not reveal ordered occupancy representing sulfatide
in the crystal lattice, suggesting that sulfatide does not permeate the crystal lattice but exerts its stabilizing effect by alternative
interactions such as on the external surface of insulin crystals. Conclusions. Sulfatide is known to stabilize insulin crystals, and we
demonstrate here that in beta cells sulfatide is likely coating insulin crystals. However, there is no evidence for sulfatide to be built
into the crystal lattice.
1. Introduction
In beta cells of the islets of Langerhans, insulin is stored in
granules as part of a crystalline insulin structure [1]. These
molecular entities are formed within the Golgi apparatus
known to contain zinc (Zn)molecules [1, 2]. Upon exocytosis
into the bloodstream, the insulin crystals revert to a hex-
americ entity and subsequently transition into a monomeric
biologically active form [3, 4]. It has been demonstrated that
the glycosphingolipid, sulfated beta-galactosylceramide, also
denominated sulfatide, acts as a chaperone for insulin during
its folding prior to resolution into insulin crystals [5] and that
sulfatide preserves these insulin crystals [5].Within beta cells,
sulfatide is present within the Golgi and insulin granules, as
well as at the membrane surface [6].
The purpose of this current study was to characterize the
relationship between insulin and sulfatide in order to gain
additional understanding as to the importance of this associ-
ation with metabolism and, potentially, aberrations related to
this process that might influence health (i.e., diabetes, insulin
resistance).Themain question to be answered in this study is
whether sulfatide is built into the crystals or is managing its
preservation effect just by being attached to the surface of the
insulin crystal.
2. Materials and Methods
2.1. Purification of Insulin. The human insulin gene (Novo
Nordisk, Bagsvaerd, Denmark) was cloned into the pAK721
vector for expression in Saccharomyces cerevisiae. The native
C-peptide was replaced by a synthetic minipeptide AAK,
connecting the A- and B-chains, and pure insulin was
obtained as earlier described [7].
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2.2. Cocrystallization of Insulin-Sulfatide Complexes. Insulin
and sulfatide (Avanti Polar Lipids, Inc., Alabaster, AL, USA)
were mixed in a 1 : 3 molar ratio, and crystals were grown
using the hanging drop vapor diffusion method [7, 8]. Pre-
liminary screens were performed using sparse-matrix crys-
tallization to determine initial conditions [9]. Crystals were
grown in conditions that contain zinc acetate or magnesium
sulfate as in previous studies [5]. Conditions were optimized
based on the crystals grown in 1.6mol/L magnesium sulfate
and 0.1mol/L MES pH 6.5. Large crystals (up to 200𝜇m
in the longest dimension) were obtained in five days in
1.3mol/L magnesium sulfate and 0.1mol/L MES pH 7.5. The
single crystal used for the data reported was grown in a
hanging drop containing 2 𝜇L protein solution (10mg/mL
+ 10.3mmol/L sulfatide) and 3 𝜇L reservoir solution. All
crystallization trials were performed at 22∘C.
2.3. X-Ray Data Collection. Data was collected on beamline
X6A at the National Synchrotron Light Source (Brookhaven
National Laboratories, Upton, NY, USA). Images were col-
lected using an ADSC 210 CCD detector and indexed and
scaled using HKL2000 [10]. XPREP [11] was used to assist
space group determination. The selected insulin/sulfatide
crystal was cryoprotected using paraffin oil, cooled in a
stream of gaseous nitrogen. The crystal was mounted at
a distance of 120mm from the detector and at an X-ray
wavelength of 0.9322 A˚. 300 frames were collected, 8 seconds
per image, with 0.5∘ oscillation steps for each frame. The
molecular replacement software PHASER-MR implemented
in PHENIXwas used for phasing. PHENIX.REFINE: 1.9 1692
was used for refinement. PDB code 2INS [12] was the initial
model used for phasing. Difference electron density maps
were created comparing electron density of the crystal versus
electron density explained by the model.
2.4. Electron Microscopy. Islet tissue was obtained from 9-
week-old male Lewis rats purchased from Taconic Bio-
sciences, Inc. (Hudson, NY, USA). The islets were isolated
using a collagenase method [13]. Isolated islets were incu-
bated overnight at 4∘Cwith the sulfatide-specificmonoclonal
antibody, Sulph I (gift from Pam Fredman), diluted as 1 : 1000
[14], and after washing in 1% PBS-BSA, the islets were
incubated overnight at 4∘C with 1 nm gold labeled goat anti-
mouse IgG (BBI Solutions, Cardiff, UK) diluted as 1 : 300 in
1% PBS-BSA and absorbed with rat serum. The islets were
postfixed after washing in 2% glutaraldehyde for 2 h and
washed in distilled water, before silver enhancement using
AURION R-GENT SE-EM (Aurion, Wageningen, NL). The
islets were washed in distilled water before osmication in
1% OsO4 diluted in 0.1M cacodylate buffer. After washing
in 0.1M cacodylate buffer, the specimens were dehydrated
in alcohol and embedded in Epon Resin 812 before ultra-
sections were examined in a Philips 208 electronmicroscope.
3. Results
Staining of beta cells for sulfatide demonstrated a close
relationship to the insulin crystals even at exocytosis
Table 1: X-ray diffraction data for insulin crystalized in the presence
of sulfatide.
PDB 4XC4
Resolution range (A˚) 30–1.5 (1.553–1.499)
Space group R3:H
Unit cell
𝑎 = 81.61, 𝑏 = 81.61,
and 𝑐 = 33.73; 𝛼 = 90, 𝛽 = 90,
and 𝛾 = 120
Total reflections (unique) 11,654 (1,124)
Completeness (%) 86.62 (82.71)
Mean 𝐼/sigma(𝐼) 18.52 (2.60)
Wilson 𝐵-factor 20.27
R-work 0.2180 (0.3020)
R-free 0.2540 (0.3595)
Number of nonhydrogen
atoms 870
Macromolecules 865
Residues 101
RMS (bonds) 0.008
RMS (angles) 1.06
Ramachandran favored (%) 95
Ramachandran allowed (%) 4.01
Ramachandran outliers (%) 0.99
𝐵-factor 29.00
Macromolecules 29.00
Ligands 33.50
(Figure 1(a)). As sulfatide has previously been noted to pro-
mote stability of insulin crystals within pancreatic beta cells
[5], we investigated the molecular mechanisms supporting
an integral role for sulfatide in insulin crystal formation
and preservation. We cocrystallized human insulin with
sulfatide in the presence of Zn (Figure 1(b)) and observed
that crystals containing insulin bound to sulfatide appeared
in a rhombohedral lattice, the same space group that has been
reported for insulin molecules found in pancreatic tissue
[15, 16]. The crystals were completely translucent to visible
light and did not display precipitation either on the surface or
within. X-ray diffraction datawas collected to 1.6 A˚ resolution
and reduced to a primitive rhombohedral lattice,H3 (Table 1).
The unit cell parameters were 𝑎 = 𝑏 = 81.61 A˚, 𝑐 = 33.729 A˚,
with 𝛼 = 𝛽 = 90.0∘, 𝛾 = 120.0∘. Matthew’s coefficient of
1.88 A˚3Da−1 is consistent with the presence of one insulin
molecule per asymmetric unit [17].
The structure was solved by molecular replacement [12]
and refined yielding statistics shown in Table 1, deposited in
the Protein Data Bank as code 4XC4. Difference electron
density maps revealed ordered water molecules and Zn in
positions consistent with other hexameric insulin structures
(Figures 1(c) and 1(d)) [5, 16]. Ordered electron density
consistent with sulfatidewas not observed.These data suggest
that sulfatide does not stabilize insulin crystals through a
mechanism involving stable contacts with insulin residues.
Journal of Diabetes Research 3
(a) (b)
(c) (d)
Figure 1: (a) Electron microscopy of a beta cell stained for sulfatide with colloidal gold granules as secondary indications. Close relationship
to the insulin crystals is clearly seen. At the surface at the beta cells an insulin crystal close to exocytosis is clearly seen at one quartile from
the right in the horizontal axis and half down in the vertical axis. (b) Upon crystallization, insulin formed hexamers of approximately 100 𝜇m
diameter. ((c) and (d)) Structure of insulin crystallized in the presence of sulfatide shows classic features of zinc bound insulin hexamers. (c)
The crystals structure of insulin (PDB code 4XC4). Zinc is depicted as gray spheres. (d) An electron density map surrounding the disulfide
bond linking cysteine chain A 20 to cysteine chain B 19.
4. Discussion
In this study we have shown that sulfatide is closely related to
and covers the insulin crystals in vivo. Furthermore, sulfatide
is known to preserve insulin crystals in spite of our present
findings that sulfatide is not integrated inside the matrix.
Beta cells must store large quantities of insulin within the
secretory granules in preparation for normal blood glucose
regulation. However, insulin has a tendency to fibrillate
which renders it biologically inactive. For having enough
storage, nature has solved this problem by crystallization of
insulin that cannot fibrillate. Insulin is present in beta cells as
hexamers that build into crystals thatmust be stable for weeks
but simultaneously capable of being secreted immediately on
demand of the blood glucose values.Thus, the insulin crystals
should be able to break down very quickly, dissociating into
monomers capable of binding the insulin receptor.
It has been previously demonstrated that at low pH (5.5)
with high concentration of Zn++ insulin crystals are well
preserved in presence of sulfatide [5]. At exocytosis of
the insulin granules and thereby insulin secretion, the pH
increases to 7.4 and the Zn++ concentration is lowered, poten-
tiating monomerization. We hypothesized that sulfatide may
act as a chaperone for insulin and preserve its crystals within
the beta cell granule due to integration of the glycolipid into
the insulin crystal. The present study suggests that sulfatide
is coating the outside of the insulin crystals (as opposed to
binding within the insulin crystal lattice), which is consistent
with data showing close associations in vivo. The blood
concentration of sulfatide has been noted to be lower in
patients with type 2 diabetes [18], so sulfatide might offer
a level of protection or improvement in insulin physiology.
Further, sulfatide has been noted to be present at reduced
quantities within the secretory granules of stressed beta cells
[19]. Autoantibodies against sulfatide have been documented
in patients with type 1 diabetes [20]. As being present at the
surface of the insulin crystals only, variations in the amount of
sulfatidemight be critical for the beta cells.Thus, interactions
4 Journal of Diabetes Research
between sulfatide and insulin crystals may have implications
on disease pathogenesis in both type 1 and type 2 diabetes,
which must be subject to further investigation.
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